openPR Logo
Press release

Antibody Drug Conjugate Market Opportunity Analysis

06-29-2017 12:01 PM CET | Health & Medicine

Press release from: Kuick Resarch

Ever since the first attempt in the 1980's to use antibody-based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.

The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.

Download Report:

https://www.kuickresearch.com/report-Antibody-Drug-Conjugate-Market-Opportunity-Analysis.php

With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.

The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.

“Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights:

* Global ADC Market Insight
* ADC Patent Analysis
* Orphan Status & ADC
* Favorable Market Drivers & Key Issues to be Discussed
* ADC Clinical Trial Insight by Phase & Target Indications
* ADC Profiles in Report: 201
* Majority of ADC in Preclinical Phase: 83
* Marketed ADC Clinical Profiles

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibody Drug Conjugate Market Opportunity Analysis here

News-ID: 601699 • Views: 264

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for ADC

Application Delivery Controllers (ADC) Market Technology Advancement 2018 to 202 …
The application delivery controllers market is forecast to grow at a CAGR of over 6% during forecast period (2018 - 2023). The report elaborates the complete details covering product definition, product type, and application. The report covers useful details which are categorized based on Application Delivery Controllers (ADC) production region, major players, and product type which will provide a simplified view of the Application Delivery Controllers (ADC) industry. The Application Delivery
Global Application Delivery Controller (ADC) Market Analysis Research Report 201 …
MarketResearchReports.Biz has recently announced the Latest industry research report on: "Global Application Delivery Controller (ADC) Market Research Report 2018". This report studies the global Application Delivery Controller (ADC) market status and forecast, categorizes the global Application Delivery Controller (ADC) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in United States, Europe, China, Japan, South Korea and Taiwan and other regions. An application
Application Delivery Controllers (ADC) Market, Global Analysis, Trends, Forecast …
An application delivery controller (ADC) is a computer networking device in a datacenter, usually a part of an application delivery network (ADN). It is generally deployed in data centers to optimize application performance, makes applications run faster, decreases the required bandwidth, ensures availability of applications, secure, and improves resource efficiency by offloading servers, providing deep payload inspection, and making efficient use of complex protocols. Earlier, ADC were deployed for externally-facing
Application Delivery Controllers (ADC) Market to 2025 – Analysis by QYResearch …
Qyresearchreports include new market research report “Global Application Delivery Controllers (ADC) Sales Market Report 2018” to its huge collection of research reports. The global Application Delivery Controllers (ADC) market is carefully examined in the report compiled with the use of latest research methodologies and up-to-date data. The researchers who have penned this report are experts in the subject and possess sound knowledge about the market. Moreover, they have immense experience in
SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London
Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75